16.9 C
New York
Wednesday, May 25, 2022

Vyant Bio, Inc. (VYNT) stock surged in the Pre-market; here is why?

Vyant Bio, Inc. (VYNT) stock surged in the pre-market after announcing entering a new partnership with OrganoTherapeutics. VYNT’s stock price is $1.70, gaining more than 25.93% from the previous closing price. VYNT stock closed at $1.35 at the end of the last trading session. VYNT stock volume traded in the previous trading session was around 41.08K shares. The current market cap of the company is about $33.63 million.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


VYNT inked a deal with OrganoTherapeutics

Vyant Bio, Inc. (VYNT) announced in a press release today that they have inked a partnership with OrganoTherapeutics to research the development of drugs that will help treat Parkinson’s disease.

VYNT specializes in neurodevelopment and neurodegenerative disorders, while OrganoTherapeutics is a developer of propriety patient-specific organoids that help recapitulate Parkinson’s disease pathology.

To find new PD treatments, the teams will combine their experience in drug discovery by employing human-derived cells, high-throughput biology and chemistry, and machine learning-based therapeutic design. As a team, they will work to build disease-linked, clinically-translatable tests and biomarkers using different molecular, biochemical, and cellular approaches to identify PD-rescuing medication candidates.

OrganoTherapeutic’s sophisticated induced pluripotent stem cell (iPSC) disease models and Vyant Bio’s AnalytiXTM machine learning technology will be combined and leveraged with this method.

VYNT CEO’s Remarks

As Jay Roberts, the CEO of Vyant Bio, said, medicines for disorders that impact the central nervous system (CNS) are very tough to discover: they demand real innovation and outstanding scientific skill to overcome. As part of a series of strategic actions to concentrate our efforts and accelerate our position in drug development, we have formed a partnership with a company specializing in CNS medications.


VYNT has entered into a partnership that will complement its drug development process for PD. Both the companies have expertise that will help them increase the possibilities of such a drug development that will have brighter chances of approval and will have efficient results in combating Parkinson’s disease.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles